Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AKCEA-TTR-LRx in Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis

Status:
Completed
Trial end date:
2020-02-20
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability, as well as the pharmacokinetic and pharmacodynamic profiles of single and multiple doses of AKCEA-TTR-LRx administered subcutaneously to healthy volunteers and patients with Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.